多发性骨髓瘤的缓解深度:三项PETHEMA/GEM临床试验的汇总分析
该汇总分析纳入609例新诊断多发性骨髓瘤患者,来自GEM2000、GEM2005MENOS65和GEM2010MAS65三项试验,入组后9个月评估微小残留病(MRD),中位随访71个月。结果显示,无MRD阴性的完全缓解(CR)与接近CR或部分缓解相比未延长无进展生存(PFS)和总生存(OS),而MRD阴性状态与显著延长的PFS和OS相关,且在高危细胞遗传学患者中预后优势尤为明显。作者认为MRD阴性应作为适合移植及老年fit患者的重要终点。
要点
- 无MRD阴性的CR与接近CR或部分缓解相比,中位PFS分别为27、27、29个月,中位OS分别为59、64、65个月,未见生存延长。
- MRD阴性状态与显著延长的PFS(中位63个月,P < .001)和OS(中位未达到,P < .001)相关,在各亚组中一致。
- 在高危细胞遗传学患者中,MRD阴性相较于CR的预后优势尤为明显;MRD阴性患者中位PFS达12年,10年OS率94%。
核心结论
- MRD阴性状态在PFS和OS方面的预后价值超过CR的获得,且不受治疗类型或患者危险分组影响。
- MRD阴性应被视为适合移植和老年fit多发性骨髓瘤患者最相关的终点之一。
研究设计与样本
- 汇总分析纳入609例新诊断多发性骨髓瘤患者,来自GEM2000和GEM2005MENOS65研究(适合移植)及GEM2010MAS65临床试验(老年患者),均在入组后9个月进行MRD评估,中位随访71个月。
主要发现
- 无MRD阴性的CR与接近CR或部分缓解相比,中位PFS分别为27、27、29个月,中位OS分别为59、64、65个月,未见PFS和OS延长。
- MRD阴性状态与显著延长的PFS(中位63个月,P < .001)和OS(中位未达到,P < .001)相关,在既往移植、疾病分期和细胞遗传学定义的亚组中一致。
- 在高危细胞遗传学患者中,MRD阴性相较于CR的预后优势尤为明显。
- Harrell C统计量显示,在Cox模型中纳入MRD(而非CR)评估缓解对PFS和OS的区分度更高。
- 在34例诊断时骨髓受累表型类似意义未明单克隆丙种球蛋白血症的MRD阴性患者中,中位PFS为12年,10年OS率为94%。
关键数值与推荐
- 无MRD阴性的CR组中位PFS 27个月、中位OS 59个月;接近CR组中位PFS 27个月、中位OS 64个月;部分缓解组中位PFS 29个月、中位OS 65个月。
- MRD阴性组中位PFS 63个月(P < .001),中位OS未达到(P < .001)。
- 34例MRD阴性且诊断时骨髓受累表型类似意义未明单克隆丙种球蛋白血症的患者,中位PFS 12年,10年OS率94%。
临床怎么用
- 作者认为MRD阴性应被视为适合移植和老年fit多发性骨髓瘤患者最相关的终点之一。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To perform a critical analysis on the impact of depth of response in newly diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma) 2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months after study enrollment. Median follow-up of the series was 71 months. Results Achievement of complete remission (CR) in the absence of MRD negativity was not associated with prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months, respectively). MRD-negative status was strongly associated with prolonged PFS (median, 63 months; P < .001) and OS (median not reached; P < .001) overall and in subgroups defined by prior transplantation, disease stage, and cytogenetics, with prognostic superiority of MRD negativity versus CR particularly evident in patients with high-risk cytogenetics. Accordingly, Harrell C statistics showed higher discrimination for both PFS and OS in Cox models that included MRD (as opposed to CR) for response assessment. Superior MRD-negative rates after different induction regimens anticipated prolonged PFS. Among 34 MRD-negative patients with MM and a phenotypic pattern of bone marrow involvement similar to monoclonal gammopathy of undetermined significance at diagnosis, the probability of "operational cure" was high; median PFS was 12 years, and the 10-year OS rate was 94%. Conclusion Our results demonstrate that MRD-negative status surpasses the prognostic value of CR achievement for PFS and OS across the disease spectrum, regardless of the type of treatment or patient risk group. MRD negativity should be considered as one of the most relevant end points for transplant-eligible and elderly fit patients with MM.
引用
- Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol. 2017. PMID: 28498784. doi:10.1200/JCO.2016.69.2517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。